Abstract
Tuberculosis (TB) remains the leading cause of bacterial disease-related death and is among the top 10 overall causes of death worldwide. The complex nature of this infectious lung disease has proven difficult to treat, and significant research efforts are now evaluating the feasibility of host-directed, adjunctive therapies.
Funding Information
  • Gouvernement du Canada | Canadian Institutes of Health Research (CGS-MSc)
  • Gouvernement du Canada | Canadian Institutes of Health Research (PJT-162424)
  • Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (PGS-PhD)
  • Government of Ontario (Ontario Graduate Scholarship)
  • National Sanitarium Association (Scholars Program)
  • University of Ottawa (Translational Research Grant)
  • University of Ottawa (CI3 graduate scholarship)

This publication has 123 references indexed in Scilit: